Segui
chiara funaioli
chiara funaioli
Niguarda Cancer Center, Ospedale Niguarda Ca Granda, Milan, Italy
Email verificata su ospedaleniguarda.it
Titolo
Citata da
Citata da
Anno
Phase II study of cetuximab in combination with FOLFIRI in patients with untreated advanced gastric or gastroesophageal junction adenocarcinoma (FOLCETUX study)
C Pinto, F Di Fabio, S Siena, S Cascinu, FLR Llimpe, C Ceccarelli, V Mutri, ...
Annals of Oncology 18 (3), 510-517, 2007
4112007
Real-world study of everolimus in advanced progressive neuroendocrine tumors
F Panzuto, M Rinzivillo, N Fazio, F de Braud, G Luppi, MC Zatelli, F Lugli, ...
The oncologist 19 (9), 966-974, 2014
1092014
The predictive value of 18F-FDG-PET early evaluation in patients with metastatic gastric adenocarcinoma treated with chemotherapy plus cetuximab
FD Fabio, C Pinto, FL Rojas Llimpe, S Fanti, P Castellucci, C Longobardi, ...
Gastric Cancer 10, 221-227, 2007
742007
Therapeutic implications of resistance to molecular therapies in metastatic colorectal cancer
A Sartore-Bianchi, K Bencardino, A Cassingena, F Venturini, C Funaioli, ...
Cancer treatment reviews 36, S1-S5, 2010
462010
Radiological imaging markers predicting clinical outcome in patients with metastatic colorectal carcinoma treated with regorafenib: post hoc analysis of the CORRECT phase III …
R Ricotta, A Verrioli, S Ghezzi, L Porcu, A Grothey, A Falcone, ...
ESMO open 1 (6), e000111, 2016
352016
Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic …
A Sartore-Bianchi, K Bencardino, F Di Nicolantonio, F Pozzi, C Funaioli, ...
Targeted oncology 5, 19-28, 2010
352010
Integrated molecular dissection of the epidermal growth factor receptor (EFGR) oncogenic pathway to predict response to EGFR-targeted monoclonal antibodies in metastatic …
A Sartore-Bianchi, K Bencardino, F Di Nicolantonio, F Pozzi, C Funaioli, ...
Targeted oncology 5, 19-28, 2010
352010
The impact of chemotherapy on overall survival and quality of life of patients with metastatic colorectal cancer: a review of phase III trials
C Funaioli, C Longobardi, AA Martoni
Journal of chemotherapy 20 (1), 14-27, 2008
292008
Does biomolecular characterization of stage II/III colorectal cancer have any prognostic value?
C Funaioli, C Pinto, V Mutri, F Di Fabio, C Ceccarelli, AA Martoni
Clinical colorectal cancer 6 (1), 38-45, 2006
192006
Pooled analysis of clinical outcome of patients with chemorefractory metastatic colorectal cancer treated within phase I/II clinical studies based on individual biomarkers of …
A Sartore-Bianchi, A Amatu, E Bonazzina, S Stabile, L Giannetta, G Cerea, ...
Targeted Oncology 12, 525-533, 2017
162017
18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy
C Funaioli, C Pinto, F Di Fabio, D Santini, C Ceccarelli, E De Raffaele, ...
Tumori Journal 93 (6), 611-615, 2007
152007
18FDG-PET evaluation correlates better than CT with pathological response in a metastatic colon cancer patient treated with bevacizumab-based therapy
C Funaioli, C Pinto, F Di Fabio, D Santini, C Ceccarelli, E De Raffaele, ...
Tumori Journal 93 (6), 611-615, 2007
152007
Real-world study of everolimus in advanced progressive neuroendocrine tumors
F Panzuto, M Rinzivillo, N Fazio, F de Braud, G Luppi, MC Zatelli, F Lugli, ...
The Oncologist 20 (5), 570-570, 2015
132015
Predictive value of circulating VEGF in patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma treated with cetuximab in combination with cisplatin …
F Di Fabio, C Pinto, E Bucca, S Giaquinta, AS Fabricio, V Mutri, S Michilin, ...
Journal of Clinical Oncology 26 (15_suppl), 15605-15605, 2008
72008
Prognostic significance of ki67, p53, TS and EGFR in advanced gastric and gastroesophageal junction cancer patients treated with cetuximab plus FOLFIRI (FOLCETUX study)
FL Rojas Llimpe, F Di Fabio, C Ceccarelli, C Pinto, S Siena, S Cascinu, ...
Journal of Clinical Oncology 25 (18_suppl), 4604-4604, 2007
62007
Early magnesium reduction in advanced colorectal cancer patients treated with cetuximab+ irinotecan as predictive factor of efficacy and outcome
B Vincenzi, D Santini, C Funaioli, C Pinto, F Di Fabio, S Galluzzo, ...
Journal of Clinical Oncology 26 (15_suppl), 4106-4106, 2008
32008
Evaluation of electrolytic imbalance in patients with advanced colorectal and gastric cancer treated with anti-EGFR monoclonal antibody-based therapy
C Funaioli, C Pinto, F Di Fabio, N Malavasi, P Di Tullio, S Pini, B Vincenzi, ...
Journal of Clinical Oncology 26 (15_suppl), 14631-14631, 2008
22008
Neuroimaging abnormalities in adult medulloblastoma undergoing intensified therapy
S Secondino, A Citterio, P Pedrazzoli, C Funaioli, GG Scialfa, S Siena
Anticancer research 28 (6B), 3991-3992, 2008
12008
18FDG-PET in targeted therapy with cetuximab in gastric or gastroesophageal junction (GEJ) adenocarcinoma: First results of the Italian FOLCETUX Study
F Di Fabio, C Pinto, S Fanti, FL Rojas Llimpe, C Longobardi, C Nanni, ...
Journal of Clinical Oncology 24 (18_suppl), 4061-4061, 2006
12006
An Italian multicenter retrospective real-life analysis of patients with brain metastases from renal cell carcinoma: the BMRCC study
V Internò, F Massari, R Rudà, BA Maiorano, O Caffo, G Procopio, ...
ESMO open 8 (4), 101598, 2023
2023
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20